- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06139393
Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults
November 15, 2023 updated by: Jiangsu HengRui Medicine Co., Ltd.
Study on Efficacy and Safety of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults
The study is being conducted to evaluate the efficacy, and safety of HR091506 tablets for treatment of gout with hyperuricemia in adults, and to compare the results with febuxostat tablets in the same doses.
Study Overview
Status
Not yet recruiting
Conditions
Study Type
Interventional
Enrollment (Estimated)
750
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ninghui Yan
- Phone Number: +0518-82342973
- Email: ninghui.yan@hengrui.com
Study Contact Backup
- Name: Jing Xu
- Phone Number: +0518-82342973
- Email: jing.xu.jx23@hengrui.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- 18-75 years old, male or female;
- BMI: 18.0-30.0 kg/m2;
- Meet the 2015 ACR/EULAR gout classification criteria;
- Fast serum uric acid ≥ 480 μmol/L on 2 different days during the screening perid;
- Willing to ues contraceptive measures during the study;
- Able and willing to provide a written informed consent.
Exclusion Criteria:
- History of acute gout attack within 4 weeks before randomization.
- Subjects who have undergone major surgery or organ transplantation within 3 months before randomization.
- Subjects with major cardiovascular disease within 6 months before randomization.
- History of chronic infection or recurrent infection within 1year before randomization.
- History of malignant tumor or current history of combined malignant tumor within 5 years before screening.
- History of secondary hyperuricemia, refractory gout, or xanthine metabolism disorder.
- Subjects with poorly controlled blood pressure or diabetes mellitus.
- History of chronic diffuse connective tissue disease and/or massively elevated urate diseases and/or untreated clinically significant thyroid disease.
- History of diseases that may affect the in vivo process, safety evaluation, or subjects' participation in the research.
- Abnormal laboratory tests that may affect subjects participating in the research.
- Combined use of prohibited drugs.
- Allergic to ingredient or component of the experimental drug.
- Participated in other clinical trials within 1 month before randomization.
- Pregnant or nursing women.
- History of drug abuse, drug use and/or excessive drinking within 1 year before screening.
- The inestigators determined that other conditions were inappropriate for participation in this clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment group A: HR091506 tablets + placebo of febuxostat tablets
|
HR091506 tablets 20mg qd + placebo of febuxostat tablets 20mg qd from Week 1 to 4, HR091506 tablets 40mg qd + placebo of febuxostat tablets 40mg qd from Week 5 to 28.
|
Active Comparator: Treatment group B: febuxostat tablets + placebo of HR091506 tablets
|
febuxostat tablets 20mg qd + placebo of HR091506 tablets 20mg qd from Week 1 to 4, febuxostat tablets 40mg qd + placebo of HR091506 tablets 40mg qd from Week 5 to 28.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The proportion of subjects with serum uric acid level < 360 μmoL/L at Week 28
Time Frame: Week 28
|
Week 28
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of subjects with serum uric acid level < 360 μmol/L at each visit.
Time Frame: at week 4,8,12,16,20and24 after administration
|
at week 4,8,12,16,20and24 after administration
|
Proportion of subjects with serum uric acid level < 300 μmol/L at each visit
Time Frame: at week 4,8,12,16,20and24 after administration
|
at week 4,8,12,16,20and24 after administration
|
Change of serum uric acid level from baseline to every visit
Time Frame: at week 4,8,12,16,20and24 after administration
|
at week 4,8,12,16,20and24 after administration
|
Proportion of subjects with ≥1 gout flare during treatment stage
Time Frame: during treatment stage
|
during treatment stage
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
November 1, 2023
Primary Completion (Estimated)
November 1, 2024
Study Completion (Estimated)
June 1, 2025
Study Registration Dates
First Submitted
November 15, 2023
First Submitted That Met QC Criteria
November 15, 2023
First Posted (Estimated)
November 20, 2023
Study Record Updates
Last Update Posted (Estimated)
November 20, 2023
Last Update Submitted That Met QC Criteria
November 15, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HR091506-302
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gout With Hyperuricemia in Adults
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingPrimary Gout With Hyperuricemia in Adults
-
Cairo UniversityRecruitingS.Mutans Colonization in Adults With Fixed Orthodontic ApplianceEgypt
-
Fuji Yakuhin Co., Ltd.Mochida Pharmaceutical Company, Ltd.CompletedHyperuricemia With or Without GoutJapan
-
Mochida Pharmaceutical Company, Ltd.Fuji Yakuhin Co., Ltd.CompletedHyperuricemia With or Without GoutJapan
-
Fuji Yakuhin Co., Ltd.Mochida Pharmaceutical Company, Ltd.Completed
-
Mochida Pharmaceutical Company, Ltd.Fuji Yakuhin Co., Ltd.CompletedHyperuricemia With or Without GoutJapan
-
LG ChemCompletedHyperuricemia | Gout | Qt Interval, Variation inUnited States
-
Ai PengRecruitingGout Flare | Intercritical Gout | Advanced Gout | Asymptomatic HyperuricemiaChina
-
University of MinnesotaCompleted
-
Jiangsu HengRui Medicine Co., Ltd.Completed
Clinical Trials on HR091506 tablets + placebo of febuxostat tablets
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingPrimary Gout With Hyperuricemia in Adults
-
Sun Yat-sen UniversityUnknown
-
Centre of Clinical Pharmacology, Hanoi Medical...Not yet recruitingIrritable Bowel Syndrome With DiarrheaVietnam
-
Galapagos NVCompletedCrohn's DiseaseUnited Kingdom, Belgium, France, Hungary, Russian Federation, Czech Republic, Germany, Poland, Romania
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu vcare pharmaceutical technology co., LTDRecruitingModerate to Severe Atopic DermatitisChina
-
Akros Pharma Inc.CompletedSkin Diseases | Psoriasis | Plaque PsoriasisUnited States, Canada, Poland
-
Jiangsu vcare pharmaceutical technology co., LTDCompletedInflammatory Bowel DiseasesChina
-
JKT Biopharma Co., Ltd.Recruiting